Validation of proposed prostate cancer biomarkers with gene expression data: A long road to travel

Cancer and Metastasis Reviews

Volumn 33, Issue 2-3, 2014, Pages 657-671

  Amaro, Adriana ^a   Esposito, Alessia Isabella ^a   Gallina, Anna ^a   Nees, Matthias ^b   Angelini, Giovanna ^a   Albini, Adriana ^c   Pfeffer, Ulrich ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF TURKU   (Finland)

^c S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

Biomarkers; Multivariate model; Prognostic signature; Prostate cancer; PSA

Indexed keywords

TUMOR MARKER;

CANCER GRADING; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INFORMATION PROCESSING; MALE; META ANALYSIS; METABOLISM; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; REPRODUCIBILITY;

CLUSTER ANALYSIS; DATASETS AS TOPIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; PROGNOSIS; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84905092743     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-013-9470-4     Document Type: Article

References (68)

1. Brawley, O. W. (2012). Prostate cancer epidemiology in the United States. World Journal of Urology, 30(2), 195-200. doi:10.1007/s00345-012-0824-2.
2. Center, M. M., Jemal, A., Lortet-Tieulent, J., Ward, E., Ferlay, J., Brawley, O., et al. (2012). International variation in prostate cancer incidence and mortality rates. European Urology, 61(6), 1079-1092. doi:10.1016/j.eururo. 2012.02.054.
3. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S., & Redwine, E. (1987). Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. New England Journal of Medicine, 317(15), 909-916. doi:10.1056/NEJM198710083171501 [Comparative Study Research Support, Non-U.S. Gov't]. (Pubitemid 17147932)
4. Wang, M. C., Valenzuela, L. A., Murphy, G. P., & Chu, T. M. (1979). Purification of a human prostate specific antigen. Investigative Urology, 17(2), 159-163 [Research Support, U.S. Gov't, P.H.S.]. (Pubitemid 10132507)
5. Lin, K., Lipsitz, R., Miller, T., & Janakiraman, S. (2008). Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 149(3), 192-199 [Practice Guideline Review].
6. Chou, R., & LeFevre, M. L. (2011). Prostate cancer screening - the evidence, the recommendations, and the clinical implications. JAMA: Journal of the American Medical Association, 306(24), 2721-2722. doi:10.1001/jama.2011. 1891.
7. Moyer, V. A. (2012). Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine. doi:10.1059/0003-4819-157-2-201207170-00459. E-459.
8. Andriole, G. L., Crawford, E. D., Grubb, R. L., 3rd, Buys, S. S., Chia, D., Church, T. R., et al. (2009). Mortality results from a randomized prostate-cancer screening trial. New England Journal of Medicine, 360(13), 1310-1319. doi:10.1056/NEJMoa0810696 [Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural].
9. Schroder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L., Ciatto, S., Nelen, V., et al. (2009). Screening and prostate-cancermortality in a randomized European study. New England Journal of Medicine, 360(13), 1320-1328. doi:10.1056/NEJMoa0810084 [Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't].
10. Carter, H. B., Pearson, J. D., Metter, E. J., Brant, L. J., Chan, D. W., Andres, R., et al. (1992). Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA: Journal of the American Medical Association, 267(16), 2215-2220 [Research Support, U.S. Gov't, P.H.S.].
11. Thompson, I. M., Ankerst, D. P., Chi, C., Goodman, P. J., Tangen, C. M., Lucia, M. S., et al. (2006). Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. Journal of the National Cancer Institute, 98(8), 529-534. doi:10.1093/jnci/djj131 [Research Support, N.I.H., Extramural]. (Pubitemid 43898816)
12. D'Amico, A. V., Chen, M. H., Roehl, K. A., & Catalona, W. J. (2004). Preoperative PSAvelocity and the risk of death from prostate cancer after radical prostatectomy. New England Journal of Medicine, 351(2), 125-135. doi:10.1056/NEJMoa032975.
13. Catalona, W. J., Smith, D. S., & Ornstein, D. K. (1997). Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA: Journal of the American Medical Association, 277(18), 1452-1455 [Research Support, Non-U.S. Gov't]. (Pubitemid 27208887)
14. Bussemakers, M. J., van Bokhoven, A., Verhaegh, G. W., Smit, F. P., Karthaus, H. F., Schalken, J. A., et al. (1999). DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Research, 59(23), 5975-5979 [Research Support, Non-U.S. Gov't]. (Pubitemid 30004960)
15. Filella, X., Foj, L., Mila, M., Auge, J. M., Molina, R., & Jimenez, W. (2013). PCA3 in the detection and management of early prostate cancer. Tumour Biology, 34(3), 1337-1347. doi:10.1007/s13277-013-0739-6 [Review].
16. Hessels, D., Klein Gunnewiek, J. M., van Oort, I., Karthaus, H. F., van Leenders, G. J., van Balken, B., et al. (2003). DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. European Urology, 44(1), 8-15. discussion 15-16; [Comparative Study].
17. Deras, I. L., Aubin, S. M., Blase, A., Day, J. R., Koo, S., Partin, A. W., et al. (2008). PCA3: a molecular urine assay for predicting prostate biopsy outcome. Journal of Urology, 179(4), 1587-1592. doi:10.1016/j.juro.2007.11.038 [Clinical Trial Multicenter Study Research Support, N.I.H., Extramural].
18. Haese, A., de la Taille, A., van Poppel, H., Marberger, M., Stenzl, A., Mulders, P. F., et al. (2008). Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. European Urology, 54(5), 1081-1088. doi:10.1016/j.eururo.2008.06.071 [Comparative Study Multicenter Study Research Support, Non-U.S. Gov't].
19. Marks, L. S., Fradet, Y., Deras, I. L., Blase, A., Mathis, J., Aubin, S. M., et al. (2007). PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology, 69(3), 532-535. doi:10.1016/j.urology.2006. 12.014 [Multicenter Study]. (Pubitemid 46428401)
20. van Gils, M. P., Hessels, D., Hulsbergen-van de Kaa, C. A., Witjes, J. A., Jansen, C. F., Mulders, P. F., et al. (2008). Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. The Prostate, 68(11), 1215-1222. doi:10.1002/pros.20781 [Research Support, Non-U. S. Gov't].
21. Whitman, E. J., Groskopf, J., Ali, A., Chen, Y., Blase, A., Furusato, B., et al. (2008). PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. Journal of Urology, 180(5), 1975-1978. doi:10.1016/j.juro.2008.07.060. discussion 1978-1979; [Research Support, Non-U.S. Gov't].
22. Bleyer, A., & Welch, H. G. (2012). Effect of three decades of screening mammography on breast-cancer incidence. New England Journal of Medicine, 367(21), 1998-2005. doi:10.1056/NEJMoa1206809.
23. Arbyn, M., Anttila, A., Jordan, J., Ronco, G., Schenck, U., Segnan, N., et al. (2010). European guidelines for quality assurance in cervical cancer screening. Second edition - summary document. Annals of Oncology, 21(3), 448-458. doi:10.1093/annonc/mdp471 [Practice Guideline Research Support, Non-U.S. Gov't].
24. Lieberman, D. A. (2009). Clinical practice. Screening for colorectal cancer. New England Journal of Medicine, 361(12), 1179-1187. doi:10.1056/NEJMcp0902176 [Review].
25. Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., et al. (2004). A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New England Journal of Medicine, 351(27), 2817-2826. doi:10.1056/NEJMoa041588 [Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't]. (Pubitemid 40051905)
26. van't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A., Mao, M., et al. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415(6871), 530-536. doi:10.1038/415530a [Research Support, Non-U.S. Gov't]. (Pubitemid 34130608)
27. Pfeffer, U., Mirisola, V., Esposito, A., Amaro, A., & Angelini, G. (2013). Breast cancer genomics: from portraits to landscapes. In U. Pfeffer (Ed.), Cancer genomics: molecular classification, prognosis and response prediction. Dordrecht: Springer.
28. da Cunha Santos, G., Shepherd, F. A., & Tsao, M. S. (2011). EGFR mutations and lung cancer. Annual Review of Pathology, 6, 49-69. doi:10.1146/annurev-pathol-011110-130206 [Research Support, Non-U.S. Gov't Review].
29. Buzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J., Thomas, E. S., Theriault, R. L., et al. (2005). Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. Journal of Clinical Oncology: Official journal of the American Society of Clinical Oncology, 23(16), 3676-3685. doi:10.1200/JCO.2005.07.032 [Clinical Trial Clinical Trial, Phase III Randomized Controlled Trial Research Support, Non-U.S. Gov't].
30. Gennari, A., Sormani, M. P., Pronzato, P., Puntoni, M., Colozza, M., Pfeffer, U., et al. (2008). HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. Journal of the National Cancer Institute, 100(1), 14-20. doi:10.1093/jnci/djm252 [Meta-Analysis Research Support, Non-U.S. Gov't]. (Pubitemid 351767337)
31. Nash, A. F., & Melezinek, I. (2000). The role of prostate specific antigen measurement in the detection and management of prostate cancer. Endocrine-related Cancer, 7(1), 37-51 [Review]. (Pubitemid 30305870)
32. Christensen, E., Evans, K. R., Menard, C., Pintilie, M., & Bristow, R. G. (2008). Practical approaches to proteomic biomarkers within prostate cancer radiotherapy trials. Cancer Metastasis Reviews, 27(3), 375-385. doi:10.1007/s10555-008-9139-6 [Research Support, Non-U.S. Gov't Review].
33. Bibault, J. E., Fumagalli, I., Ferte, C., Chargari, C., Soria, J. C., & Deutsch, E. (2013). Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review. Cancer Metastasis Reviews. doi:10.1007/s10555-013-9419-7.
34. Nadler, R. B., Humphrey, P. A., Smith, D. S., Catalona, W. J., & Ratliff, T. L. (1995). Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. Journal of Urology, 154(2 Pt 1), 407-413 [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
35. Herschman, J. D., Smith, D. S., & Catalona, W. J. (1997). Effect of ejaculation on serum total and free prostate-specific antigen concentrations. Urology, 50(2), 239-243. doi:10.1016/S0090-4295(97)00209-4 [Research Support, Non-U.S. Gov't]. (Pubitemid 27339940)
36. da Huang, W., Sherman, B. T., & Lempicki, R. A. (2009). Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Research, 37(1), 1-13. doi:10.1093/nar/gkn923 [Research Support, N.I.H., Extramural].
37. Kilpinen, S., Autio, R., Ojala, K., Iljin, K., Bucher, E., & Sara, H. (2008). Systematic bioinformatic analysis of expression levels of 17, 330 human genes across 9,783 samples from 175 types of healthy and pathological tissues. Genome Biology, 9(9), R139. doi:10.1186/gb-2008-9-9-r139 [Research Support, Non-U.S. Gov't].
38. Sboner, A., Demichelis, F., Calza, S., Pawitan, Y., Setlur, S. R., Hoshida, Y., et al. (2010). Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Medical Genomics, 3, 8. doi:10.1186/1755-8794-3-8 [Research Support, N.I. H., Extramural].
39. Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., et al. (2010). Integrative genomic profiling of human prostate cancer. Cancer Cell, 18(1), 11-22. doi:10.1016/j.ccr.2010.05.026 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
40. Yu, Y. P., Landsittel, D., Jing, L., Nelson, J., Ren, B., Liu, L., et al. (2004). Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. Journal of Clinical Oncology, 22(14), 2790-2799. doi:10.1200/JCO.2004.05.158 [Research Support, U.S. Gov't, P.H.S.]. (Pubitemid 41079896)
41. Chandran, U. R., Ma, C., Dhir, R., Bisceglia, M., Lyons-Weiler, M., Liang, W., et al. (2007). Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer, 7, 64. doi:10.1186/1471-2407-7-64 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
42. Vanaja, D. K., Ballman, K. V., Morlan, B. W., Cheville, J. C., Neumann, R. M., Lieber, M. M., et al. (2006). PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer. Clinical Cancer Research, 12(4), 1128-1136. doi:10.1158/1078-0432.CCR-05-2072 [Research Support, N.I.H., Extramural]. (Pubitemid 43342500)
43. Bartholow, T. L., Chandran, U. R., Becich, M. J., & Parwani, A. V. (2011). Immunohistochemical profiles of claudin-3 in primary and metastatic prostatic adenocarcinoma. Diagnostic Pathology, 6, 12. doi:10.1186/1746-1596-6- 12 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
44. Kristiansen, G., Fritzsche, F. R., Wassermann, K., Jager, C., Tolls, A., Lein, M., et al. (2008). GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. British Journal of Cancer, 99(6), 939-948. doi:10.1038/sj.bjc.6604614.
45. Marin, L. V., Ferariu, D., & Mihailovici, M. S. (2010). Immunohistochemic staining for CK5/6 and P63 significance in prostate premalignant lesions and adenocarcinoma. Revista medico-Chirurgicala A Societatii de Medici si Naturalisti din Iasi, 114(3), 818-822.
46. Shariat, S. F., Ashfaq, R., Roehrborn, C. G., Slawin, K. M., & Lotan, Y. (2005). Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia. Journal of Urology, 174(5), 2046-2050. doi:10.1097/01.ju. 0000176459.79180.d1 [Comparative Study Research Support, Non-U.S. Gov't]. (Pubitemid 41547021)
47. Edwards, S., Campbell, C., Flohr, P., Shipley, J., Giddings, I., TePoele, R., et al. (2005). Expression analysis onto microarrays of randomly selected cDNA clones highlights HOXB13 as a marker of human prostate cancer. British Journal of Cancer, 92(2), 376-381. doi:10.1038/sj.bjc.6602261 [Comparative Study Research Support, Non-U.S. Gov't]. (Pubitemid 40343155)
48. Bieberich, C. J., Fujita, K., He, W. W., & Jay, G. (1996). Prostate-specific and androgen-dependent expression of a novel homeobox gene. The Journal of Biological Chemistry, 271(50), 31779-31782. (Pubitemid 26422192)
49. Pfeffer, U. (Ed.). (2013). Cancer genomics: molecular classification, prognosis and response prediction. Dordrecht: Springer.
50. Hu, Y., Wang, M., Veverka, K., Garcia, F. U., & Stearns, M. E. (2007). The ABCA5 protein: a urine diagnostic marker for prostatic intraepithelial neoplasia. Clinical Cancer Research, 13(3), 929-938. doi:10.1158/1078-0432.CCR-06-1718. (Pubitemid 46340369)
51. Morgan, R., Boxall, A., Bhatt, A., Bailey, M., Hindley, R., Langley, S., et al. (2011). Engrailed-2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancer. Clinical Cancer Research, 17(5), 1090-1098. doi:10.1158/1078-0432.CCR-10-2410 [Research Support, Non-U.S. Gov't].
52. Montgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., et al. (2008). Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Research, 68(11), 4447-4454. doi:10.1158/0008-5472.CAN-08-0249 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.].
53. Xu, L., Tan, A. C., Naiman, D. Q., Geman, D., & Winslow, R. L. (2005). Robust prostate cancer marker genes emerge from direct integration of inter-study microarray data. Bioinformatics, 21(20), 3905-3911. doi:10.1093/bioinformatics/bti647 [Evaluation Studies Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. (Pubitemid 41535506)
54. Malhotra, S., Lapointe, J., Salari, K., Higgins, J. P., Ferrari, M., & Montgomery, K. (2011). A tri-marker proliferation index predicts biochemical recurrence after surgery for prostate cancer. PLoS ONE, 6(5), e20293. doi:10.1371/journal.pone.0020293 [In Vitro Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
55. Romanuik, T. L., Ueda, T., Le, N., Haile, S., Yong, T. M., Thomson, T., et al. (2009). Novel biomarkers for prostate cancer including noncoding transcripts. The American Journal of Pathology, 175(6), 2264-2276. doi:10.2353/ajpath.2009.080868 [Research Support, N. I.H., Extramural Research Support, Non-U.S. Gov't].
56. Gleason, D. F. (1977). The Veteran's Administration Cooperative Urologic Research Group: histologic grading and clinical staging of prostatic carcinoma. In M. Tannenbaum (Ed.), Urologic pathology: the prostate (pp. 171-198). Philadelphia: Lea and Febige.
57. Dupuy, A., & Simon, R. M. (2007). Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. Journal of the National Cancer Institute, 99(2), 147-157. doi:10.1093/jnci/djk018 [Guideline Review].
58. da Huang, W., Sherman, B. T., & Lempicki, R. A. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protocols, 4(1), 44-57. doi:10.1038/nprot.2008.211 [Research Support, N.I.H., Extramural].
59. Chen, X., Xu, S., McClelland, M., Rahmatpanah, F., Sawyers, A., Jia, Z., et al. (2012). An accurate prostate cancer prognosticator using a seven-gene signature plus Gleason score and taking cell type heterogeneity into account. PLoS ONE, 7(9), e45178. doi:10.1371/journal.pone.0045178.
60. Penney, K. L., Sinnott, J. A., Fall, K., Pawitan, Y., Hoshida, Y., Kraft, P., et al. (2011). mRNA expression signature of Gleason grade predicts lethal prostate cancer. Journal of Clinical Oncology, 29(17), 2391-2396. doi:10.1200/JCO.2010.32.6421 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
61. Olmos, D., Brewer, D., Clark, J., Danila, D. C., Parker, C., Attard, G., et al. (2012). Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. The Lancet Oncology. doi:10.1016/S1470-2045(12)70372-8.
62. Pfeffer, U., Romeo, F., Noonan, D. M., & Albini, A. (2009). Prediction of breast cancer metastasis by genomic profiling: where do we stand? Clinical & Experimental Metastasis, 26(6), 547-558. doi:10.1007/s10585-009- 9254-y [Research Support, Non-U.S. Gov't Review].
63. Reis-Filho, J. S., & Pusztai, L. (2011). Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet, 378(9805), 1812-1823. doi:10.1016/S0140-6736(11)61539-0 [Research Support, Non-U.S. Gov't Review].
64. Sorlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America, 98(19), 10869-10874. doi:10.1073/pnas.191367098 [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. (Pubitemid 32878711)
65. Barbieri, C. E., Baca, S. C., Lawrence, M. S., Demichelis, F., Blattner, M., Theurillat, J. P., et al. (2012). Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nature Genetics. doi:10.1038/ng.2279.
66. Grasso, C. S., Wu, Y. M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., et al. (2012). The mutational landscape of lethal castration-resistant prostate cancer. Nature, 487(7406), 239-243. doi:10.1038/nature11125 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.].
67. Gandellini, P., Profumo, V., Folini, M., & Zaffaroni, N. (2011). MicroRNAs as new therapeutic targets and tools in cancer. Expert Opinion on Therapeutic Targets, 15(3), 265-279. doi:10.1517/14728222.2011.550878 [Review].
68. Sogno, I., Conti, M., Consonni, P., Noonan, D. M., & Albini, A. (2012). Surface-activated chemical ionization-electrospray ionization source improves biomarker discovery with mass spectrometry. Rapid Communications in Mass Spectrometry, 26(10), 1213-1218. doi:10.1002/rcm.6208 [Research Support, Non-U.S. Gov't].